• Aliases: SGN-35, cAC10-vcMMAE
    • CD30-directed (chimeric) antibody–drug conjugate that targets CD30, a protein expressed on the surface of certain cancer cells
    • FDA approved for anaplastic large cell lymphoma, CD30-expressing mycosis fungoides, or Hodgkin lymphoma
    • Recommended dose: 1.8 mg/kg up to a maximum of 180 mg as IV infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity (1.2 mg/kg for mild hepatic impairment)
    • Metabolism: Major CYP3A4 and P-glycoprotein substrate
    • Common side effects: Myelosuppression, fatigue, infusion-related side effects, nausea/vomiting, diarrhea, peripheral sensory/motor neuropathy, pyrexia, upper respiratory tract infection (cough), rash, multifocal leukoencephalopathy (rare) (US box warning)
    Other topics in Targeted and Immunotherapy Agents